Probing the glioma micro-environment: Analysis using biopsy in combination with ultra-fast cyclic immunolabeling.

Fine-needle biopsy Glial tumors Multiplex imaging

Journal

Neoplasia (New York, N.Y.)
ISSN: 1476-5586
Titre abrégé: Neoplasia
Pays: United States
ID NLM: 100886622

Informations de publication

Date de publication:
12 Sep 2024
Historique:
received: 27 06 2024
revised: 03 09 2024
accepted: 04 09 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

The interaction between gliomas and the immune system is poorly understood and thus hindering development of effective immunotherapies for glioma patients. The immune response is highly variable during tumor development, and affected by therapies such as surgery, radiation, and chemotherapy. Currently, analysis of these local changes is difficult due to poor accessibility of the tumor and high-morbidity of sampling. In this study, we developed a model for repeat-biopsy in mice to study these local immunological changes over time. Using fine needle biopsy we were able to safely and repeatedly collect cells from intracranial tumors in mice. Ultra-fast cycling technology (FAST) was used for multi-cycle immunofluorescence of retrieved cells, and provided insights in the changing immune response over time. The combination of these techniques can be utilized to study changes in the immune response in glioma or other intracranial diseases over time, and in response to treatment within the same animal.

Identifiants

DOI: 10.1016/j.neo.2024.101051 PMID: 39270598
pubmed: 39270598
pii: S1476-5586(24)00093-9
doi: 10.1016/j.neo.2024.101051
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101051

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RW is a consultant to ModeRNA, Boston Scientific, Lumicell, Seer Biosciences, Earli, and Accure Health, none of whom contributed to this research. Other authors declare that they have no competing interests.

Auteurs

Thomas S van Solinge (TS)

Departments of Neurology and Radiology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School, Boston, MA, USA; Department of Neurosurgery, Leiden University Medical Center, Leiden, the Netherlands.

Juhyun Oh (J)

Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Erik Abels (E)

Departments of Neurology and Radiology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School, Boston, MA, USA; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.

Peter Koch (P)

Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.

Xandra O Breakefield (XO)

Departments of Neurology and Radiology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School, Boston, MA, USA.

Ralph Weissleder (R)

Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, USA. Electronic address: rweissleder@mgh.harvard.edu.

Marike L D Broekman (MLD)

Departments of Neurology and Radiology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School, Boston, MA, USA; Department of Neurosurgery, Leiden University Medical Center, Leiden, the Netherlands; Department of Neurosurgery, Haaglanden Medical Center, The Hague, the Netherlands. Electronic address: m.l.d.broekman@lumc.nl.

Classifications MeSH